Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.

ESC Heart Fail · 2020 · PMC7755023 · PMID 33586910

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

borderline significantP = 0.05actually significant

A borderline significant reduction in the composite of HF hospitalization or cardiovascular death was seen with SGLT2 inhibitor use [HR: 0.80 (0.63–1.00); P = 0.05; I 2 = 29%].

also in 11,409 other papers

nominally significantno p-value reported

While DAPA‐HF trial showed a nominally significant reduction in cardiovascular and all‐cause mortality, EMPEROR‐Reduced and SOLOIST‐WHF did not.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.